147992-80-1

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-4-(dimethylamino)pyridine-3-carbonitrile is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to facilitate the creation of diverse drug molecules. Its unique structural features allow for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-chloro-4-(dimethylamino)pyridine-3-carbonitrile is employed as a versatile building block, enabling the construction of complex organic molecules. Its presence in reactions can lead to the formation of a wide array of heterocyclic compounds, which are essential in various chemical and pharmaceutical applications.
Used as a Nucleophilic Catalyst:
2-chloro-4-(dimethylamino)pyridine-3-carbonitrile is utilized as a nucleophilic catalyst in various chemical reactions. Its catalytic properties can enhance the efficiency of synthetic processes, making it a valuable tool in the development of new chemical methodologies and the improvement of existing ones.

Upstream product

• 62321-91-9 3-Cyano-4-(dimethylamino)-2-(1H)-pyridone 
• 91945-90-3 2-[1,3-bis(dimethylaminoallylidene)]malononitrile 
• 14164-26-2 α-Cyano-β-dimethylaminocrotononitrile 
• 62321-91-9 C₈H₉N₃O 
• 98694-71-4 2-[1,3-bis(dimethylaminoallylidene)]malononitrile 

Downstream Products

• 331857-03-5 5-amino-4-dimethylaminothieno[8,9-b]pyridine-6-carboxylic acid methyl ester 
• 147992-86-7 3-Amino-4-dimethylamino-thieno[2,3-b]pyridine-2-carboxylic acid ethyl ester 
• 159583-14-9 3-(4-Chloro-phenyl)-9-dimethylamino-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one 
• 159583-12-7 3,4-dihydro-3-benzyl-9-dimethylaminopyrido-<3,2:4',5'>thieno<3,2-d>pyrimidin-4-one 
• 159583-15-0 9-Dimethylamino-3-p-tolyl-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one 
• 159583-13-8 9-dimethylamino-3-phenyl-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one 
• 147992-87-8 3-amino-4-(dimethylamino)thieno[2,3-b]pyridine-2-carboxamide 
• 869802-58-4 A-841720 

Relevant academic research and scientific papers

FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part

Fused tricyclic mGIuR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGlu

mGluR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF

The present invention discloses compounds of general formula (I) wherein X1-X4 and R1-R3 are as defined in the description. The present invention also discloses methods of treatment for pain, neurodegeneration and convulsive states in a host mammal in need thereof, and pharmaceutical compositions including those compounds.

Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists

SAR (structure-activity relationship) studies of triazafluorenone derivatives as potent mGluR1 antagonists are described. The triazafluorenone derivatives are non-amino acid derivatives and noncompetitive mGluR1 antagonists that bind at a putative alloste